Gut Liver.
2023 Mar;17(2):343-343. 10.5009/gnl210585.e.
Corrigendum to: Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
- Affiliations
-
- 1Department of Internal Medicine, Pusan National University College of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
- KMID: 2540425
- DOI: http://doi.org/10.5009/gnl210585.e
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
- Role of Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer
- Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer
- Updates of Chemotherapy for Pancreatic Cancer
- Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
